All patients
subjects at risk
chloroquine and derivatives in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
0.80 [0.52 ; 1.24 ] HYDRA (Hernandez-Cardenas), 2021 1 0% 214 NA not evaluable deathsdetailed results Duke University hydroxychloroquine/azithromycine, 2020 0.50 [0.01; 19.56]
Galan, 2021 (REV) 1.06 [0.58; 1.95]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
Mahevas, 2020 0.61 [0.13; 2.88]
Yu, 2020 0.32 [0.16; 0.63]
0.66 [0.41 ; 1.09 ] Duke University hydroxychloroquine/azithromycine, 2020, Galan, 2021 (REV), HYDRA (Hernandez-Cardenas), 2021, Mahevas, 2020, Yu, 2020 5 46% 1,044 serious not evaluable deaths (time to event analysis only)detailed results Galan, 2021 (REV) 1.06 [0.58; 1.95]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
Yu, 2020 0.32 [0.16; 0.63]
0.67 [0.36 ; 1.25 ] Galan, 2021 (REV), HYDRA (Hernandez-Cardenas), 2021, Yu, 2020 3 73% 950 serious not evaluable clinical deteriorationdetailed results Mahevas, 2020 0.93 [0.48; 1.81]
0.93 [0.48 ; 1.81 ] Mahevas, 2020 1 0% NA not evaluable clinical improvement (time to event analysis only)detailed results HYDRA (Hernandez-Cardenas), 2021 1.05 [0.74; 1.48]
1.05 [0.74 ; 1.48 ] HYDRA (Hernandez-Cardenas), 2021 1 0% 214 NA not evaluable hospital dischargedetailed results HYDRA (Hernandez-Cardenas), 2021 1.01 [0.72; 1.42]
1.01 [0.72 ; 1.42 ] HYDRA (Hernandez-Cardenas), 2021 1 0% 214 NA not evaluable mechanical ventilationdetailed results Galan, 2021 0.14 [0.03; 0.71]
0.14 [0.03 ; 0.71 ] Galan, 2021 1 0% 168 NA not evaluable ICU admissiondetailed results Galan, 2021 1.42 [0.68; 2.99]
1.42 [0.68 ; 2.99 ] Galan, 2021 1 0% 168 NA not evaluable off oxygenationdetailed results HYDRA (Hernandez-Cardenas), 2021 0.98 [0.64; 1.51]
0.98 [0.64 ; 1.51 ] HYDRA (Hernandez-Cardenas), 2021 1 0% 214 NA not evaluable 0.0 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-08-04 12:55 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 91
- treatments: 508,656,657,832
- roots T: 290